- The share
- Press releases
- Financial calendar
- Financial reports
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Contact us
- Thank you
XPS™ to Switzerland
The XPS™ is the only system on the market for Ex Vivo Lung Perfusion (EVLP) that is approved on all major markets, including US approval by the FDA. The XPS™ system gives the user the flexibility to perform evaluation of lungs for transplantation using a standardized and simplified procedure. The XPS™ has achieved good clinical results when used at leading clinics in the USA and Europe. In Europe, five clinics will have the XPS™-system, whereof one clinic in Switzerland..
“We are very pleased that the clinic in Lausanne, which is one of the most important clinics in Switzerland, now starts to use XPS™ to facilitate EVLP," says Magnus Nilsson, CEO of XVIVO Perfusion.
January 29, 2016
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101, firstname.lastname@example.org
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication on January 29, 2016 at 8:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.